 | Up a level |
Grob, J. -J., Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., Haney, P., Kaempgen, E., Karaszewska, B., Mauch, C., Miller, W. H., Jr., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S. and Hauschild, A. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann. Oncol., 25 (7). S. 1428 - 1437. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Schliemann, C., Pink, D., Floercken, A., Ahrens, M., Egerer, G., Goetze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D. and Kessler, T. (2021). A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma. Ann. Oncol., 32. S. S1127 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041